148 related articles for article (PubMed ID: 6090371)
1. Phase I trials of WR-2721 and cis-platinum.
Glover D; Glick JH; Weiler C; Yuhas J; Kligerman MM
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1781-4. PubMed ID: 6090371
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II trials of WR-2721 and cis-platinum.
Glover D; Glick JH; Weiler C; Fox K; Turrisi A; Kligerman MM
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1509-12. PubMed ID: 3019969
[TBL] [Abstract][Full Text] [Related]
3. Clinical trials of WR-2721 and cis-platinum.
Glover D; Grabelsky S; Fox K; Weiler C; Cannon L; Glick J
Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1201-4. PubMed ID: 2541121
[TBL] [Abstract][Full Text] [Related]
4. Phase I controlled trials of WR-2721 and cyclophosphamide.
Glick JH; Glover D; Weiler C; Norfleet L; Yuhas J; Kligerman MM
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1777-80. PubMed ID: 6090370
[TBL] [Abstract][Full Text] [Related]
5. Protection by WR-2721 against radiation plus cis-diamminedichloroplatinum II caused injury to colonic epithelium in mice.
Ito H; Komaki R; Milas L
Int J Radiat Oncol Biol Phys; 1994 Mar; 28(4):899-903. PubMed ID: 8138443
[TBL] [Abstract][Full Text] [Related]
6. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial.
Glover D; Glick JH; Weiler C; Hurowitz S; Kligerman MM
J Clin Oncol; 1986 Apr; 4(4):584-8. PubMed ID: 3007686
[TBL] [Abstract][Full Text] [Related]
7. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.
Glover D; Glick JH; Weiler C; Fox K; Guerry D
J Clin Oncol; 1987 Apr; 5(4):574-8. PubMed ID: 3031224
[TBL] [Abstract][Full Text] [Related]
8. A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
Gradishar WJ; Stephenson P; Glover DJ; Neuberg DS; Moore MR; Windschitl HE; Piel I; Abeloff MD
Cancer; 2001 Nov; 92(10):2517-22. PubMed ID: 11745184
[TBL] [Abstract][Full Text] [Related]
9. Protection by WR-2721 of human bone marrow function following irradiation.
Constine LS; Zagars G; Rubin P; Kligerman M
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1505-8. PubMed ID: 2428794
[TBL] [Abstract][Full Text] [Related]
10. Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide.
Yuhas JM; Spellman JM; Jordan SW; Pardini MC; Afzal SM; Culo F
Br J Cancer; 1980 Oct; 42(4):574-85. PubMed ID: 6254555
[TBL] [Abstract][Full Text] [Related]
11. [Renal protection with amifostine during intraoperative peritoneal chemohyperthermia (IPCH) with cisplatin (CDDP) for peritoneal carcinosis. Phase 1 study].
Vaira M; Barone R; Aghemo B; Mioli PR; De Simone M
Minerva Med; 2001 Aug; 92(4):207-11. PubMed ID: 11535965
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity, induction of cross-resistance, and nephrotoxicity of a new platinum analogue, cis-1,1-diaminomethylcyclohexaneplatinum(II) sulfate, and of cis-diamminedichloroplatinum(II) in an immunocytoma model in the LOU/M rat.
de Jong WH; Steerenberg PA; Vos JG; Bulten EJ; Verbeek F; Kruizinga W; Ruitenberg EJ
Cancer Res; 1983 Oct; 43(10):4927-34. PubMed ID: 6683993
[TBL] [Abstract][Full Text] [Related]
13. Toxicity of WR-2721 administered in single and multiple doses.
Kligerman MM; Glover DJ; Turrisi AT; Norfleet AL; Yuhas JM; Coia LR; Simone C; Glick JH; Goodman RL
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1773-6. PubMed ID: 6090369
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical trials of WR-2721 with alkylating agent chemotherapy.
Glick JH; Glover DJ; Weiler C; Blumberg A; Nelson D; Yuhas JM; Kligerman M
Int J Radiat Oncol Biol Phys; 1982; 8(3-4):575-80. PubMed ID: 6286556
[No Abstract] [Full Text] [Related]
15. Protection by WR-3689 against gamma-ray-induced intestinal damage: comparative effect on clonogenic cell survival, mouse survival, and DNA damage.
Murray D; Altschuler EM; Hunter N; Milas L
Radiat Res; 1989 Nov; 120(2):339-51. PubMed ID: 2559423
[TBL] [Abstract][Full Text] [Related]
16. Alterations in oxygen transport following WR-2721.
Glover D; Negendank W; Delivoria-Papadopoulos M; Glick JH
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1565-8. PubMed ID: 6090363
[TBL] [Abstract][Full Text] [Related]
17. Cis-diamminedichloroplatinum (II) by 5-day continuous infusion. A new dose schedule with minimal toxicity.
Salem P; Khalyl M; Jabboury K; Hashimi L
Cancer; 1984 Feb; 53(4):837-40. PubMed ID: 6537893
[TBL] [Abstract][Full Text] [Related]
18. Radioprotection of normal tissues against gamma rays and cyclotron neutrons with WR-2721: LD50 studies and 35S-WR-2721 biodistribution.
Rasey JS; Nelson NJ; Mahler P; Anderson K; Krohn KA; Menard T
Radiat Res; 1984 Mar; 97(3):598-607. PubMed ID: 6328565
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin nephrotoxicity. Correlation with plasma platinum concentrations.
Kelsen DP; Alcock N; Young CW
Am J Clin Oncol; 1985 Feb; 8(1):77-80. PubMed ID: 4039530
[TBL] [Abstract][Full Text] [Related]
20. Phase I trials of WR2721 in combination with radiation therapy and with the alkylating agents cyclophosphamide and cis-platinum.
Kligerman MM; Blumberg AL; Glick JH; Nelson DF; Glover D; Yuhas JM; Amols HI; Goodman RL
Cancer Clin Trials; 1981; 4(4):469-74. PubMed ID: 6274534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
